886 research outputs found
Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991-2010 (Automated Childhood Cancer Information System): a population-based study.
A deceleration in the increase in cancer incidence in children and adolescents has been reported in several national and regional studies in Europe. Based on a large database representing 1·3 billion person-years over the period 1991-2010, we provide a consolidated report on cancer incidence trends at ages 0-19 years.
We invited all population-based cancer registries operating in European countries to participate in this population-based registry study. We requested a listing of individual records of cancer cases, including sex, age, date of birth, date of cancer diagnosis, tumour sequence number, primary site, morphology, behaviour, and the most valid basis of diagnosis. We also requested population counts in each calendar year by sex and age for the registration area, from official national sources, and specific information about the covered area and registration practices. An eligible registry could become a contributor if it provided quality data for all complete calendar years in the period 1991-2010. Incidence rates and the average annual percentage change with 95% CIs were reported for all cancers and major diagnostic groups, by region and overall, separately for children (age 0-14 years) and adolescents (age 15-19 years). We examined and quantified the stability of the trends with joinpoint analyses.
For the years 1991-2010, 53 registries in 19 countries contributed a total of 180 335 unique cases. We excluded 15 162 (8·4%) of 180 335 cases due to differing practices of registration, and considered the quality indicators for the 165 173 cases included to be satisfactory. The average annual age-standardised incidence was 137·5 (95% CI 136·7-138·3) per million person-years and incidence increased significantly by 0·54% (0·44-0·65) per year in children (age 0-14 years) with no change in trend. In adolescents, the combined European incidence was 176·2 (174·4-178·0) per million person-years based on all 35 138 eligible cases and increased significantly by 0·96% (0·73-1·19) per year, although recent changes in rates among adolescents suggest a deceleration in this increasing trend. We observed temporal variations in trends by age group, geographical region, and diagnostic group. The combined age-standardised incidence of leukaemia based on 48 458 cases in children was 46·9 (46·5-47·3) per million person-years and increased significantly by 0·66% (0·48-0·84) per year. The average overall incidence of leukaemia in adolescents was 23·6 (22·9-24·3) per million person-years, based on 4702 cases, and the average annual change was 0·93% (0·49-1·37). We also observed increasing incidence of lymphoma in adolescents (average annual change 1·04% [0·65-1·44], malignant CNS tumours in children (average annual change 0·49% [0·20-0·77]), and other tumours in both children (average annual change 0·56 [0·40-0·72]) and adolescents (average annual change 1·17 [0·82-1·53]).
Improvements in the diagnosis and registration of cancers over time could partly explain the observed increase in incidence, although some changes in underlying putative risk factors cannot be excluded. Cancer incidence trends in this young population require continued monitoring at an international level.
Federal Ministry of Health of the Federal German Government, the European Union's Seventh Framework Programme, and International Agency for Research on Cancer
2018 MAX-C/ExoMars Mission: The Orleans Mars-Analogue Rock Collection for Instrument Testing
International audienceIn order to reply to the exobiological goals of the 2018 MAX-C/ExoMars mission, the Orléans-OSUC analogue rock collection and database contains well characterised Mars analogue rocks and minerals for use in instrument testing and in situ missions
What are we measuring? A critique of range of motion methods currently in use for Dupuytren's disease and recommendations for practice
Background: Range of motion is the most frequently reported measure used in practice to evaluate outcomes.
A goniometer is the most reliable tool to assess range of motion yet, the lack of consistency in reporting prevents comparison between studies. The aim of this study is to identify how range of motion is currently assessed and reported in Dupuytren’s disease literature. Following analysis recommendations for practice will be made to enable consistency in future studies for comparability. This paper highlights the variation in range of motion reporting in Dupuytren’s disease.
Methods: A Participants, Intervention, Comparison, Outcomes and Study design format was used for the search strategy and search terms. Surgery, needle fasciotomy or collagenase injection for primary or recurrent Dupuytren’s disease in adults were included if outcomes were monitored using range of motion to record change. A literature search was performed in May 2013 using subject heading and free-text terms to also capture electronic publications ahead of print. In total 638 publications were identified and following screening 90 articles met the inclusion criteria. Data was extracted and entered onto a spreadsheet for analysis. A thematic analysis was carried out to establish any duplication, resulting in the final range of motion measures identified.
Results: Range of motion measurement lacked clarity, with goniometry reportedly used in only 43 of the 90 studies, 16 stated the use of a range of motion protocol. A total of 24 different descriptors were identified describing range of motion in the 90 studies. While some studies reported active range of motion, others reported passive or were unclear. Eight of the 24 categories were identified through thematic analysis as possibly describing the same measure, ‘lack of joint extension’ and accounted for the most frequently used. Conclusions: Published studies lacked clarity in reporting range of motion, preventing data comparison and
meta-analysis. Percentage change lacks context and without access to raw data, does not allow direct comparison of baseline characteristics. A clear description of what is being measured within each study was required. It is recommended that range of motion measuring and reporting for Dupuytren’s disease requires consistency to address issues that fall into 3 main categories:-
Definition of terms
Protocol statement
Outcome reportin
Optimal functional outcome measures for assessing treatment for Dupuytren's disease: A systematic review and recommendations for future practice
This article is available through the Brunel Open Access Publishing Fund. Copyright © 2013 Ball et al.; licensee BioMed Central Ltd.Background: Dupuytren's disease of the hand is a common condition affecting the palmar fascia, resulting in progressive flexion deformities of the digits and hence limitation of hand function. The optimal treatment remains unclear as outcomes studies have used a variety of measures for assessment. Methods: A literature search was performed for all publications describing surgical treatment, percutaneous needle aponeurotomy or collagenase injection for primary or recurrent Dupuytren’s disease where outcomes had been monitored using functional measures. Results: Ninety-one studies met the inclusion criteria. Twenty-two studies reported outcomes using patient reported outcome measures (PROMs) ranging from validated questionnaires to self-reported measures for return to work and self-rated disability. The Disability of Arm, Shoulder and Hand (DASH) score was the most utilised patient-reported function measure (n=11). Patient satisfaction was reported by eighteen studies but no single method was used consistently. Range of movement was the most frequent physical measure and was reported in all 91 studies. However, the methods of measurement and reporting varied, with seventeen different techniques being used. Other physical measures included grip and pinch strength and sensibility, again with variations in measurement protocols. The mean follow-up time ranged from 2 weeks to 17 years. Conclusions: There is little consistency in the reporting of outcomes for interventions in patients with Dupuytren’s disease, making it impossible to compare the efficacy of different treatment modalities. Although there are limitations to the existing generic patient reported outcomes measures, a combination of these together with a disease-specific questionnaire, and physical measures of active and passive individual joint Range of movement (ROM), grip and sensibility using standardised protocols should be used for future outcomes studies. As Dupuytren’s disease tends to recur following treatment as well as extend to involve other areas of the hand, follow-up times should be standardised and designed to capture both short and long term outcomes
Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
INTRODUCTION: FibroScan\u27s M and XL probes give significantly different results, which could lead to misevaluation of liver fibrosis if the correct probe is not chosen. According to the manufacturer, the M probe should be used when the skin-liver capsule distance (SCD) is <25 mm, and the XL probe should be used when SCD is ≥25 mm. We aimed at validating this recommendation and defining the conditions of use for FibroScan probes in clinical practice.
METHODS: Four hundred thirty-nine patients with biopsy-proven chronic liver disease were included. Of them, 382 had successful examinations with both M and XL probes. Advanced fibrosis was defined as Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) F ≥3 or Metavir F ≥2.
RESULTS: In a same patient, XL probe results were significantly lower than M probe results: 7.9 (5.6-11.7) vs 9.5 (6.7-14.6) kPa, respectively (P < 0.001). After matching for age, sex, liver fibrosis, and serum transaminases, M probe results in patients with SCD <25 mm and XL probe results in those with SCD ≥25 mm did not significantly differ: 8.8 (6.0-12.0) vs 9.1 (6.7-12.8) kPa, respectively (P = 0.175). Of note, 81.4% of patients with body mass index (BMI) <32 kg/m had SCD <25 mm, and 77.7% of patients with BMI ≥32 kg/m had SCD ≥25 mm. A practical algorithm using BMI first and then the FibroScan Automatic Probe Selection tool was proposed to help physicians accurately choose which probe to use in clinical practice.
CONCLUSIONS: There is no significant difference in results between M and XL probes when they are used in the right conditions. In clinical practice, the probe should be selected according to the BMI and the Automatic Probe Selection tool
Nucleon-induced reactions at intermediate energies: New data at 96 MeV and theoretical status
Double-differential cross sections for light charged particle production (up
to A=4) were measured in 96 MeV neutron-induced reactions, at TSL laboratory
cyclotron in Uppsala (Sweden). Measurements for three targets, Fe, Pb, and U,
were performed using two independent devices, SCANDAL and MEDLEY. The data were
recorded with low energy thresholds and for a wide angular range (20-160
degrees). The normalization procedure used to extract the cross sections is
based on the np elastic scattering reaction that we measured and for which we
present experimental results. A good control of the systematic uncertainties
affecting the results is achieved. Calculations using the exciton model are
reported. Two different theoretical approches proposed to improve its
predictive power regarding the complex particle emission are tested. The
capabilities of each approach is illustrated by comparison with the 96 MeV data
that we measured, and with other experimental results available in the
literature.Comment: 21 pages, 28 figure
Pion and Sigma Polarizabilities and Radiative Transitions
Fermilab E781 plans measurements of gamma-Sigma and -pion
interactions using a 600 GeV beam of Sigmas and pions, and a virtual photon
target. Pion polarizabilities and radiative transitions will be measured in
this experiment. The former can test a precise prediction of chiral symmetry;
the latter for a_1(1260) ----> pi + gamma is important for understanding the
polarizability. The experiment also measures polarizabilities and radiative
transitions for Sigma hyperons. The polarizabilities can test predictions of
baryon chiral perturbation theory. The radiative transitions to the
Sigma*(1385) provide a measure of the magnetic moment of the s-quark. Previous
experimental and theoretical results for gamma-pi and gamma-Sigma interactions
are given. The E781 experiment is described.Comment: 13 pages text (tex), Tel Aviv U. Preprint TAUP 2204-94, uses
Springer-Verlag TEX macro package lecproc.cmm (appended at end of tex file,
following \byebye), which requires extracting lecproc.cmm and putting this
file in your directory in addition to the tex file (mmcd.tex) before tex
processing. lecproc.cmm should be used following instructions and guidelines
available from Springer-Verlag. Submitted to the Proceedings of Workshop on
Chiral Dynamics, Massachusetts Institute of Technology, July 1994, Eds. A.
Bernstein, B. Holstein. Replaced Oct. 4 to add TAUP preprint number. Replaced
Oct. 12 to correct Pb target thickness from 1.3% interaction to 0.3
Hyperon weak radiative decays in chiral perturbation theory
We investigate the leading-order amplitudes for weak radiative decays of
hyperons in chiral perturbation theory. We consistently include contributions
from the next-to-leading order weak-interaction Lagrangian. It is shown that
due to these terms Hara's theorem is violated. The data for the decays of
charged hyperons can be easily accounted for. However, at this order in the
chiral expansion, the four amplitudes for the decays of neutral hyperons
satisfy relations which are in disagreement with the data. The asymmetry
parameters for all the decays can not be accounted for without higher-order
terms. We shortly comment on the effect of the 27-plet part of the weak
interaction.Comment: 8 pages of REVTeX and using macro-package "feynman.tex" (available at
http://xxx.lanl.gov/ftp/hep-ph/papers/macros) for the 2 figure
Report of the Workshop on Guidance on Development of Operational Methods for the Evaluation of the MSFD Criterion D3.3 (WKIND3.3i)
Mammalian Comparative Sequence Analysis of the Agrp Locus
Agouti-related protein encodes a neuropeptide that stimulates food intake. Agrp expression in the brain is restricted to neurons in the arcuate nucleus of the hypothalamus and is elevated by states of negative energy balance. The molecular mechanisms underlying Agrp regulation, however, remain poorly defined. Using a combination of transgenic and comparative sequence analysis, we have previously identified a 760 bp conserved region upstream of Agrp which contains STAT binding elements that participate in Agrp transcriptional regulation. In this study, we attempt to improve the specificity for detecting conserved elements in this region by comparing genomic sequences from 10 mammalian species. Our analysis reveals a symmetrical organization of conserved sequences upstream of Agrp, which cluster into two inverted repeat elements. Conserved sequences within these elements suggest a role for homeodomain proteins in the regulation of Agrp and provide additional targets for functional evaluation
- …